Lifewire and The Harbour School Join Hands for the “e.a.r.t.h. Project” ACN Newswire

Lifewire and The Harbour School Join Hands for the “e.a.r.t.h. Project”

15 6 月, 2022
HONG KONG, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - Lifewire and The Harbour School join hands to honour Hong Kong's cultural history with the 'e.a.r.t.h. Project', breathing new life to the century-old Tai Tam Tuk Raw Water Pumping Station Staff Quarters Compound monuments. The site will be re-imagined as an early years campus for The Harbour School (THS), a K to Grade 12 international school well known for its world-class marine science program and inclusive ethos. Named the Earth Campus, it will provide approximately 150 places for children aged 3-8 (from PN - K3 initially). With its proximity to the Tai Tam Waterworks Heritage Trail featuring Hong Kong's rich waterworks, architectural and engineering history, the Earth Campus will also serve as an open space for education, leisure and cultural activities for the public, including guided tours, nature-related activities, wellbeing programmes, arts and music events. A Water Gallery displaying the history of the water supply in Hong Kong and the historical significance of the monuments, a new Annex with a viewing platform at the roof to allow the public to appreciate the front facade of the Pumping Station, the waterfront and nearby environment and social activity cum display areas will be set up for the public. As a highlight of Batch VI of Revitalisation Scheme from the HKSAR Government, the e.a.r.t.h. project is expected to be completed in 2028. The campus design will take into account the principle of "minimum intervention" and "reversibility" to preserve all characters defining elements of the monuments. Guided tours will be provided to educate the public about the architectural history of the Tai Tam Tuk area, as well as the revitalisation process of the monuments and their surrounding areas. Efforts will be made to collaborate with the community and like-minded NGOs to provide job opportunities for those in underprivileged families, including at-risk youths. Lifewire is a registered charitable institution with a vision to empower those in need in society and child patients with rare diseases and their families through supporting education and its future development. Its partner, THS, is an international school with forward-looking values and provides differentiated instruction for mainstream and neuro-diverse students. It is internationally recognised for its high-quality, award-winning experiential learning programs, and was named Best International School in Hong Kong Living's Education Awards 2021 for its outstanding social studies curriculum and technology program. At the International School Awards 2022, THS won for its marine science program and was also a Merit Winner in the Green Council's first Sustainable Development Goals (SDG) Achievement Awards. Ms. Rita Pang, Director of Lifewire Foundation Limited and Founder of See Change Education, said: "We feel very grateful to have this opportunity to reimagine the e.a.r.t.h. Project together with support from the government and the community including the Tai Tam Tuk Village Residents Fraternity Association, Tai Tam Tuk Dragon Boat Association, Scout Association of Hong Kong, etc. We are excited to work with education visionaries at the THS to set the platinum standard for inclusive schools in the future. Earth Campus will not only provide students with a unique environment for experiential learning that is rare in Hong Kong, but also serves as a scenic hub for the community to develop an appreciation for culture, history and heritage conservation."Dr. Jadis Blurton, Head of School of THS, said: "We are honoured and grateful to be working with Lifewire, the government and the community on this project of immense importance to Hong Kong's cultural history. The Earth Campus's waterside location provides an ideal setting for our award-winning marine science and social studies programs which are experiential, interdisciplinary, active and hands-on. THS welcomes diversity in our student body and has been delivering innovative approaches to learning since 2007 that benefit a wide range of learner abilities and put the joy back into learning and school. We are also excited by the opportunity to design activities to share with and educate interested members of the public about this site's fascinating architecture, ecology, and heritage."Ms. Carolyn Campbell, Parent of THS, said "The Harbour School's inclusive ethos and individualised education meant that all three of my children are able to go to the same school, including my child with additional learning needs who otherwise would not be able to access the local state curriculum. The Earth campus will enable access to high-quality education for all types of learners." 'e.a.r.t.h.' represents 'eco', 'art & culture', 'revitalisation', 'technology' and 'heritage', and it broadly captures the goals of the project to revitalise the Tai Tam Tuk Raw Water Pumping Station Staff Quarters Compound site using green construction with an emphasis on preserving heritage, conserving ecology, and promoting art, science and culture. The site includes extensive grounds which will provide nature-based and outdoor educational opportunities for its students. Alongside the school campus, we will establish a Water Gallery to promote the Tanka Boat Culture and the history of Hong Kong's waterworks. Bringing together the beauty of nature and education, our plan shall include guided eco-tours, mangrove planting, nature walks, wellness events, and other family-friendly leisure activities to encourage public participation and appreciation of the area and the Tai Tam Waterworks Heritage Trail. About LifewireLifewire (www.lifewire.hk) is a registered charitable institution founded in 2014. It is committed to bringing together corporates, chambers of commerce, organisations, and volunteer teams from all walks of life to help rare disease child patients and their families with medical and daily expenses, providing support and counseling, and spreading awareness about rare diseases to the society. Since its establishment, Lifewire has raised over HK$18 million for over 600 families. Its mission also encompasses life education, as Lifewire regularly visits campus to share the life stories of children who suffer from rare diseases, hoping to empower and encourage those children with rare diseases and inspire students to learn from them. About The Harbour SchoolThe Harbour School (THS) is a K to Grade 12 international school that aims to unlock the best in every student by taking a highly individual approach to teaching. The school was founded in 2007 and is already gaining a worldwide reputation as a center of excellence. It applies international best practices in adapting the US curriculum with an emphasis on 21st-century skills such as problem-solving, communication, teamwork, creativity and innovation. THS was named Best International School in Hong Kong Living's Education Awards 2021 where it also won awards for outstanding social studies curriculum and technology program. At the International School Awards 2022, THS won for its marine science program and was also a Merit Winner in the Green Council's first Sustainable Development Goals (SDG) Achievement Awards. For more information, please visit: www.ths.edu.hkMedia Inquiries:Yuki Lee (852) 3758 8355 yuki.lee@asiaalliedgroup.comSophie Po (852) 3758 8337 sophie.po@asiaalliedgroup.comNatalie Shiu (852) 3758 8366 natalie.shiu@asiaalliedgroup.comMaria Copp (852) 3905 0180 mariacopp@ths.edu.hkTo download all high-resolution images, please visit:https://www.dropbox.com/sh/wotmhbwi06s80oy/AABjE4mDJirLknt_Rrar_cCAa?dl=0 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
中国抗体在美国完成SM17 I期临床试验首例健康受试者给药 ACN Newswire

中国抗体在美国完成SM17 I期临床试验首例健康受试者给药

15 6 月, 2022
HONG KONG, Jun 15, 2022 - (亚太商讯 via SEAPRWire.com) - 中国抗体制药有限公司（“中国抗体”或“公司”，连同其附属公司，统称“集团”；股份代号：3681.HK），专注研究、开发、制造及商业化免疫性疾病疗法的香港生物制药公司，欣然宣布，其一类新药（First-in-Class）SM17（注射用人源化抗IL-17RB单克隆抗体）在美国完成其I期临床试验之首例健康受试者给药，目前受试者情况正常。SM17是一款全球首创针对IL-17RB靶点的人源化IgG4-κ单克隆抗体。SM17最初由LifeArc（英国领先的医药研究慈善组织）与Andrew McKenzie博士共同开发并委托授权给中国抗体进行后续的临床研究与商业化。Andrew McKenzie博士（英国皇家学会会员）也是我们中国抗体科学顾问委员会成员。SM17结合IL-17RB受体后，可抑制人白细胞介素25（IL-25，一类关键的“警戒素”）导致的Th2细胞相关免疫反应，而IL-25已被证明与气道细胞的病毒感染以及过敏性疾病如哮喘的病理变化有关。患有未受控制的严重哮喘疾病患者，会承受哮喘反复发作及住院的风险；未受控制的严重哮喘疾病也会引起死亡率及患病率的升高、生活质素的下降以及医疗支出的增加等一系列问题。公司相信靶向Th2细胞相关炎性上游细胞因子通路（例如IL-17RB）的疗法，将能够在较前端从相关免疫级联反应控制哮喘等气道炎性相关疾病的发生及进展。公司相信SM17有潜力满足现有哮喘治疗中未满足的医疗需求。FIH的I期临床试验主要是在健康受试者中进行单次递增剂量（SAD）研究和多次递增剂量（MAD）研究，目的在于研究SM17在健康受试者中的安全性、耐受性、药效及相关药物代谢反应。SM17新药研究申请（IND）于2022年3月11日获得美国食品药品监督管理局（FDA）批准。尽管疫情爆发，中国抗体依旧快速在美国启动I期临床试验之首例健康受试者给药计划。此次I期临床试验的启动是中国抗体与LifeArc合作的重要里程碑，也从侧面验证了中国抗体在新药研发方面的的高效执行力。LifeArc首席执行官Melanie Lee提到：“LMB在抗体研发领域已深耕多年，LifeArc与Andrew McKenzie博士共同合作开发了SM17。Andrew McKenzies博士研究开发靶向IL-17RB的临床候选药物，然后利用LifeArc的人源化技术将靶向IL-17RB的抗体候选药物人源化，最终得到我们的人源化抗IL-17RB单抗。之后，LifeArc授权中国抗体进一步进行SM17的临床研究与后续商业化开发。我们很高兴SM17已经在美国启动I期临床试验，并完成首例健康受试者给药，希望SM17的顺利开发能够为现有疗法无法改善病情的严重不受控制的疾病患者带来福音。”中国抗体主席、执行董事兼首席执行官梁瑞安博士表示：“SM17已在I期临床试验中顺利完成首例健康受试者给药，SM17 I期临床试验的顺利启动是整个管线研究开发过程的一个重要里程碑。继旗舰产品SM03临床III期病人入组完成，预计2023年申请新药上市，核心产品SN1011适应症范围不断扩大，不同适应症的新药研究申请不断获得监管机构获批并计划在今年开展多项适应症的II期临床试验后，我们的SM17又顺利的进入I期临床，并完成首例健康受试者给药。公司产品管线的不断丰富进一步证明公司同时推进多项研发项目的能力。我们对SM17的临床开发以及商业化机会充满信心，我们将继续加快推进项目，坚持独立创新的理念，为患者谋求福祉、为股东创造价值。”关于LifeArcLifeArc是一家以自筹资金为主，英国领先的医药研究慈善组织。它通过与学术界、工业界、慈善机构和患者团体等展开合作，发掘早期新药项目，帮助新药的研究以满足广大患者未被满足的医疗需求。它在伦敦设有办事处，在斯蒂夫尼奇和爱丁堡设有科研机构，以及一支在伦敦弗朗西斯·克里克研究所工作的专业科学团队。关于中国抗体制药有限公司中国抗体制药有限公司专注于研究、开发、制造及商业化免疫性疾病疗法。公司注重创新研发，其旗舰产品SM03为全球首项用以治疗类风湿关节炎的潜在抗CD22单抗，已在中国进入类风湿关节炎三期临床试验，并被列为国家十三五重大新药创制专项重大项目。此外还有多个同类靶点首创（First-in-target）及同类首创（First-in-class）在研药物，部分已处于临床阶段，适应症范围覆盖类风湿性关节炎、系统性红斑狼疮、寻常型天疱疮、非霍奇金氏淋巴瘤、哮喘等具有重大未满足临床需求的疾病。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S. ACN Newswire

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.

15 6 月, 2022
HONG KONG, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, today announced that, the first healthy subject has been dosed in the Phase I clinical trial of SM17 in the U.S. SM17 is a First-in-Class (FIC) humanized anti-IL-17RB monoclonal antibody. The subject is currently in a normal condition.SM17 is the world's first humanized IgG4-k monoclonal antibody targeting IL-17RB. SM17 is currently under development by SinoMab, and was engineered by LifeArc (a leading medical research charity based in the United Kingdom). SM17 was originally developed by Dr. Andrew McKenzie, FRS, who also serves as a member of the Company's Scientific Advisory Board, at the MRC Laboratory of Molecular Biology (LMB).SM17 could suppress Th2 immune responses by binding to IL-17RB on Type 2 Innate Lymphoid cells (ILC2s), blocking a cascade of responses induced by interleukin-25 (IL-25). IL-25 is a critical cytokine classified as "alarmin", which has shown to be implicated in the pathogenesis of airway viral responses and allergic diseases, such as uncontrolled severe asthma. Uncontrolled severe asthma is associated with increased mortality/ morbidity, diminished quality of life and increased health expenditures. These patients are at a risk of recurrent asthma exacerbations and hospitalizations. The Company expected that targeting upstream mediators of the Th2 inflammatory cascade, such as IL-17RB on ILC2s, will have a broad effect on airway inflammation. The Company believes the huge potential of SM17 could satisfy unmet medical needs in asthma treatment. The Phase I study is a Single Ascending Dose (SAD) and Multiple Ascending Doses (MAD) to investigate the safety, tolerability and pharmacokinetics of SM17 in healthy subjects.SM17 received Investigational New Drug (IND) approval from U.S. Food and Drug Administration (FDA) on 11 March 2022. Despite the pandemic, SinoMab have soon initiated the first-in-human dose in the Phase I clinical trial. This marks a significant milestone on the collaboration between SinoMab and LifeArc, and demonstrates the efficient implementation of SinoMab's new drug R&D programs.Melanie Lee, Chief Executive Officer of LifeArc, said: "We applied our antibody capabilities when working with Dr. Andrew McKenzie at the LMB, to firstly generate and select a clinical candidate antibody targeting IL-17RB, and then humanise it. After evaluating and choosing the lead candidate, it was licensed to SinoMab to take forward into clinical development and towards patients. It's so rewarding to know that this antibody is going into trials and could eventually make a difference to people with severe asthma."Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: "SM17's successful first-in-human dosing in Phase I clinical trial marked another milestone in our pipeline development. Following our flagship product, SM03 and key product, SN1011, we now have another key asset entering the clinical trial stage. This further assures our potential commercialization prospects and proves our capability for progressing multiple assets of R&D concurrently. We are confident of the enormous prospects for SM17's clinical development as well as our commercialization opportunities in general. Moving forward, we will accelerate implementation of our projects, adhere to our vision of independent innovation to bring benefits to patients and create value for shareholders."About LifeArcLifeArc is a self-financing and leading UK medical research charity. It partners and works with academics, industry, charities and patient groups to unlock the potential of early stage science. It has an office in London and scientific research facilities in Stevenage and Edinburgh. It also has a specialist science team working at the Francis Crick Institute in London.About SinoMab BioScience LimitedSinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Sarawak Consolidated Industries Berhad Welcomes New Batch of Trainees for Industrial Training ACN Newswire

Sarawak Consolidated Industries Berhad Welcomes New Batch of Trainees for Industrial Training

15 6 月, 2022
KUCHING, MALAYSIA, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - Sarawak Consolidated Industries Berhad (SCIB), a civil engineering specialist, is pleased to welcome a new batch of trainees from Institut Latihan Perindustrian Kota Samarahan (ILPKS), Sarawak, to the Company for physical training as part of the industrial training programme in their final year.Rosland bin Othman, Managing Director and Chief Executive Officer of SCIBILPKS was established by the Department of Manpower under the Ministry of Human Resources in 1999, to meet the needs of Malaysia's skilled workforce by providing vocational training at the intermediate level with specialisation in high-tech fields and in-line with the need for technological developments in the manufacturing sector.The trainees were accepted into the programme following a Memorandum of Understanding (MoU) signed between the SCIB and ILP Kota Samarahan in October 2020. The MoU gives opportunities for industrial students to undergo training; offers industrial instructors places for industrial attachment training; offer job opportunities to qualified Institut Latihan Jabatan Tenaga Manusia graduates and offers short-term courses to SCIB employees who want to upgrade their skills.At the ILPKS Convocation Ceremony today, Managing Director and Chief Executive Officer of SCIB, Encik Rosland bin Othman, said, "Professional management on human capital is what we strive to do in SCIB. The younger generations are the future of any institution and even the country and that is why we must focus on the youth as they are the foundation of our society.""We provide them with a platform to learn and grow, thus giving them better understanding of their craft and the industry. Employment shall be given to promising students as well. We also believe that providing opportunity for our employees to expand their knowledge, expertise and experience with the course."Over the years, SCIB has trained approximately 179 trainees with specific skillsets such as engineering, accounting, business management and construction, while pursuing their certification, diploma and degree. These skillsets allowed the trainees to be employed in their chosen careers. Several trainees had the opportunity to be a part of the SCIB family.Sarawak Consolidated Industries Bhd: 9237 [BURSA: SCIB], scib@scib.com.my, http://scib.com.my Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
iRad于今年内开设三间全新医学扫描诊断中心 ACN Newswire

iRad于今年内开设三间全新医学扫描诊断中心

14 6 月, 2022
HONG KONG, Jun 14, 2022 - (亚太商讯 via SEAPRWire.com) - 黑桃资本有限公司（「黑桃资本」）旗下的医疗健康业务卓智医疗控股有限公司（「iRad」）刚宣布，为针对香港市场对影像诊断服务持续上升的需求，其于2022年的首半年已开设多三间医学扫描诊断中心，为客户提供全面的医学扫描诊断服务，包括磁力共振（MRI）、计算机扫描（CT Scan）、2D和3D乳房造影、超声波和X光等。同时iRad继续与多间国际知名保险公司、政府机构、著名私家医生、本地医疗集团、跨国企业、香港上市公司及非牟利机构展开合作，藉此扩阔强大的客户网络。iRad市场总监Crystal Yeung女士及iRad行政总裁Kin Wong先生继今年第一季开幕的旺角雅兰中心13楼后，iRad在6月上旬于中环核心商业地段再度扩张，选址中环皇后大道中139号 The L. Place 12及13楼全层，毗邻多幢甲级商业大厦，距离中环中心（The Center）的士站更是少于30秒的步行路程。顾客可于The L. Place门前上落车，方便一众行动不便的人士。此中心更增添共三部新型号MRI及CT扫描仪器，确保为顾客提供更高影像质素。iRad行政总裁Kin Wong先生表示：「iRad为独立医疗机构，我们并不隶属任何医疗集团。作为香港最具规模的私营专业医学扫描诊断中心，iRad成立至今近17年，我们与时并进，不断加装更多高端仪器和吸纳不同专业医疗人才，一直致力为每位病人及合作伙伴提供最佳的医疗体验。由于人口老化等问题对医疗系统带来压力，加上社会健康意识提高，更多人希望透过全身磁力共振（Whole Body MRI）来进行检查，及早发现身体异常的情况。现时，iRad合共拥有7间扫描诊断中心，其医疗团队更拥有约120名员工，包括放射科医生、放射科技师、护士和支持人员，服务近80万位病人。在医疗数据全数码化的趋势下，我们今年亦会对现有的基建系统进行技术升级，使医生能够更快捷地收到病人影像，满足电子化实时存盘需求，大大缩短报告时间，令整个过程更具效率。｣有关黑桃资本有限公司黑桃资本有限公司乃何猷龙先生的家族办公室，负责管理何先生的私人资产发及财富项目。总部设于香港，公司的全球投资组合包涵广泛的跨境投资项目，而公司亦致力发掘新的投资机遇。黑桃资本的投资策略旨在广泛覆盖地理区域及行业，同时保持多元化资产类别，投资组合包括股票、债券、医疗科技、文化产业、绿色能源、房地产和上市前投资的项目。于2021年7月，由黑桃资本附属公司为作为发起人的特殊目的收购公司Black Spade Acquisition Co（纽交所股份代号：BSAQ）于纽约证券交易所挂牌上市。有关卓智医疗控股有限公司卓智医疗控股有限公司是香港最大的专业医学扫描诊断集团。卓智医疗成立于2006年，现已发展成为领先的医学扫描诊断平台，并拥有多个服务点，提供全面的医学扫描诊断服务包括磁力共振 （MRI）、计算机扫描（CT Scan）、2D和3D乳房造影、超声波和X光。卓智医疗为公营及私营医疗机构提供服务，并与不同的非政府机构建立合作伙伴关系，目的是使公众能够获得医学扫描诊断服务。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
TOYOTA GAZOO Racing wins fifth Le Mans 24 Hours JCN Newswire

TOYOTA GAZOO Racing wins fifth Le Mans 24 Hours

14 6 月, 2022
TOKYO, Jun 14, 2022 - (JCN Newswire via SEAPRWire.com) - TOYOTA GAZOO Racing stormed to victory in the 90th Le Mans 24 Hours to extend its winning run to five at the legendary Circuit de la Sarthe.Sebastien Buemi, Brendon Hartley and Ryo Hirakawa drove a brilliant race in their #8 GR010 HYBRID, completing 380 laps to take the chequered flag in front of a passionate crowd.The team's fourth one-two finish at Le Mans was secured by last year's winners, Mike Conway, Kamui Kobayashi and Jose Maria Lopez, in their #7 GR010 HYBRID, which crossed the line just 2mins 1.222secs behind in second.Sebastien's fourth win sets a new victory record for Swiss drivers while Brendon's third triumph makes him New Zealand's most successful Le Mans driver. A first win for Ryo, in his third Le Mans and his first with TOYOTA GAZOO Racing, makes him the fifth Japanese driver to stand in the centre of the podium.The two GR010 HYBRID Hypercars were the class of the field and engaged in a close battle at the front, with the lead changing hands several times as the race ebbed and flowed, with traffic, slow zones and track evolution all coming into play.That contest continued for 16 hours, with the two cars running just a few seconds apart for most of that time. But the complexion of the race changed decisively on lap 256 when Jose pulled the race-leading #7 car to the side of the track following an issue relating to the front motor.Jose performed a system reset and was able to return to the pits, where further resets solved the issue and allowed the #7 to continue at normal racing speed, albeit nearly a lap behind the new leader, Brendon in the #8 GR010 HYBRID.With closely-matched performance, that deficit proved too great for the #7 crew to overcome, despite Jose setting the fastest lap of the race within the last half hour.Brendon, following his spectacular last-minute Hyperpole on Thursday, had the honour of taking the chequered flag to win the 90th Le Mans 24 Hours. Jose followed soon after to complete a gruelling 5,177km of racing.That result earned double points towards the 2022 FIA World Endurance Championship, which puts TOYOTA GAZOO Racing on top of the manufacturers' standings after three races, 22 points ahead of Alpine. The drivers' championship is wide open, with the #8 crew just three points of the leading Alpine trio, and #7 20 behind.The focus will return to the fight for World Championship honours in just four weeks at the 6 Hours of Monza on 10 July.Akio Toyoda (Team Founder)"Congratulations to car #8! Thank you to car #7 for being part of this 1-2 finish! This year Le Mans was a 1-2 race from the beginning to the end. However, the drivers could not run comfortably through the whole race. Instead, I think all the drivers drove with some stress.From the start for 16 hours, there were no problems with both car #7 and #8, and they were competing, racing within a few seconds with each other. We were able to compete for a long time because both cars were built to the same level and ran without trouble. The drivers were also grateful for this.On the other hand, I think it was a big burden for the drivers to have two cars from the same team competing for such a long time. I think it was really hard, but the drivers continued to fight hard. I would like to thank our six drivers.However, after that, the fight ended because we couldn't continue to run both cars perfectly. Car #7 stopped on the track when the race was about to start its final eight hours. Though we could re-start our race with that car and return to the track, this forced the drivers to run with the feeling that they didn't know when the car might stop again. I feel sorry for the drivers who continue to fight despite these extreme feelings. Thank you everyone for keeping the car running until the end.In addition, Kamui also took on the role of Team Principal at Le Mans for the first time. Instead of being distant, I heard that he went and talked to engineers and mechanics, and faced the challenges that came up from everyone. Although he hasn't been able to communicate with all the members yet, and he also said that team building is a work in progress, I think the team is gradually changing. Thank you Kamui for working hard as a Team Principal.But I understand as well how you felt as a driver, that you were eager to win but the result was so regrettable. You had the fastest lap, and then Jose took it late in the race - car #7 had naturally turned into a faster car as the race went on. I wanted car #8 to secure the victory earlier, but at the same time I wanted car #7 to take the lead again - even I felt such feelings. Thank you for keeping running and sticking with the fight until the last moment.Taking both roles as a driver and as a Team Principal can make you feel so complicated. But I think it is thanks to Kamui that our two cars could compete fairly until the end of the race. I really appreciate him for taking such important roles. I was quite happy to see Kazuki and Kamui standing on the podium with different roles from previously. Car building and team building are endless battles. Please continue to encourage a team feeling. And for Kamui, keep pushing as a driver.TOYOTA GAZOO Racing was able to win Le Mans five times in a row. Thank you to our many, many fans and partners who continue to fight together. Thank you everyone. I really appreciate all for your continuous support."Kamui Kobayashi (Driver, car #7):"Congratulations to Sebastien, Brendon, Ryo and the car #8 crew. Unfortunately for car #7, we had a problem in the early morning and that cost us the race lead. We were fighting with car #8 for a long time, and we were so close. We did a really good race apart from that, so it's really a pity that it happened. That's how it goes in a 24-hour race sometimes. It's a credit to TOYOTA GAZOO Racing that we came back on track and finished on the same lap. Thanks to Mike and Jose, and the whole car crew, for the big effort this week. I appreciate the effort from everyone in the team; we came to Le Mans with the target of a one-two finish and we achieved that."Mike Conway (Driver, car #7):"I don't think this place likes us very much; there is always something. I know we won last year but we've had some tough times here. Congratulations to our team-mate in car #8, particularly Ryo. To win it on your first attempt is something else. It's always a pleasure to work with Kamui and Jose and we gave our all for the Le Mans victory but unfortunately we came up short. But it's a great one-two for the team and the fifth win in a row for TOYOTA GAZOO Racing, which is something to be proud of. I'd like to say a big thanks to all the team, at Higashi-Fuji and Cologne. There is still a World Championship to fight for and we have three races to go, so that's on my mind right now and we will keep pushing."Jose Maria Lopez (Driver, car #7):"It hurts to miss the Le Mans win. We are all competitive people and we want to win, but we also have to know how to take defeat and be happy for the team, particularly with this one-two result for TOYOTA GAZOO Racing. Congratulations to car #8; they did a great job. We did an almost perfect race and this explains the big gap to our Hypercar competitors, who all had some trouble. We managed everything to perfection. We showed we had the speed in the car and the will to win so to face an issue is tough. But thanks to the team for getting the car going again and allowing us to keep fighting. It's good to be part of a one-two for TOYOTA GAZOO Racing at Le Mans."Sebastien Buemi (Driver, car #8):"It's hard for me to express myself after that race because it's just an amazing feeling, especially to be in the centre of the podium with Ryo and Brendon. It is fantastic that we were able to win together with Ryo in his first Le Mans as part of the #8 car. He has done such a great job and I'd like to congratulate him for his performance. The whole team, and our crew, executed a perfect race without any mistakes and no damage to the car. It's an incredible feeling to win Le Mans for the fourth time, and the fifth time for TOYOTA GAZOO Racing. It will take a little bit of time before it sinks in because it's hard to realise what we achieved today."Brendon Hartley (Driver, car #8):"It's a great achievement to get a one-two at Le Mans for TOYOTA GAZOO Racing. It was a great feeling to be behind the wheel for qualifying and to get pole position, and it was even more special to take the race finish. It's the first time I've been able to do that and I was overwhelmed with emotions when I crossed the line. During the whole race you are trying not to think about the finish because we have seen what can happen in the last laps, particularly with TOYOTA. So when you cross the line, all the emotions come out and it's a great feeling. I am so happy for Ryo, who has integrated really well. We love him and he is a strong part of the team already. We also have a great relationship with the car #7 crew and it was fun to battle so hard with them for most of the race. We were flat-out for so long but after car #7 had their problem we backed off and took minimal risk."Ryo Hirakawa (Driver, car #8):"It's an honour to join the list of legends who have won Le Mans. To be honest, I still cannot believe my dream has come true today. It was such a close race for so long and we had such a great fight with car #7. Thank you to Sebastien and Brendon who have helped me a lot since I joined the team; it is an honour to drive in the same car as them. It is fantastic to have a one-two in my first Le Mans for TOYOTA GAZOO Racing and this is thanks to the hard work of the whole team. We had a perfect strategy, great pit stops and a race without any problems; I don't think we could do more."Le Mans 24 Hours - 18 Hours:1st #8 TOYOTA GAZOO Racing 380 laps2nd #7 TOYOTA GAZOO Racing +2mins 1.222secs3rd #709 Glickenhaus Racing (Briscoe/Westbrook/Mailleux) +5 laps4th #708 Glickenhaus Racing (Pla/Dumas/Derani) +10 laps5th #38 JOTA (Gonzalez/Da Costa/Stevens) +11 laps6th #9 Prema Orlen Team (Kubica/Deletraz/Colombo) +11 laps Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
碧瑶中标食环署湾仔及旺角区废物收集服务合约价值港币1.4亿 ACN Newswire

碧瑶中标食环署湾仔及旺角区废物收集服务合约价值港币1.4亿

14 6 月, 2022
HONG KONG, Jun 14, 2022 - (亚太商讯 via SEAPRWire.com) - 碧瑶绿色集团有限公司（「碧瑶」或「集团」; 股份编号：01397. HK）欣然宣布，集团获得香港特别行政区政府食物环境卫生署（「食环署」）批出两份为期五年的服务合约，总额合共约1.4亿港元，分别由2022年6月1日起于旺角区及2022年7月1日起于湾仔区提供废物收集服务。连同上述两区，碧瑶的废物收集服务将拓展至全港共五区，服务总人口约150万人，为本港废物管理市场中的领导者之一。为配合政府的「智慧城市蓝图」及「香港气候行动蓝图2050」，碧瑶于废物管理服务中全面引入各种创新科技，以提升香港人的生活质素。例如于集团的废物收集车辆上安装智能消毒喷雾装置及创新除臭管理系统，以达致最高的卫生标准。 另一方面，集团运用全球定位系统（GPS）、驾驶记录系统、手机应用程序以及二维码等不同系统，以实时管理、记录及跟进废物收集车队的情况，以确保车队的营运效率及服务质素达至最高水平。碧瑶视可持续发展为首要任务，于上述食环署合约，主动引入电动汽车，以减少碳排放及改善空气质素。与此同时，集团更引入低地台废物收集车，确保道路安全。碧瑶主席吴永康先生表示：「碧瑶欣然获得两份食环署服务合约，足証社会对集团一直以来努力改善社区环境的肯定。碧瑶的员工本身就住在所服务的社区，当然为提供最佳服务，不遗余力。为香港创建一个健康社区，高效的废物管理绝不可或缺。集团的员工一直努力不懈，以确保都市废物能得到积极、适时和专业处理。碧瑶作为香港最大及备受敬重的综合环境服务集团之一，深信我们的服务对改善香港生活环境，能起重大作用。集团亦一直致力探索各种创新绿色科技，进一步推动香港成为一个更清洁、更环保及更可持续发展的城市。」碧瑶绿色集团简介：碧瑶绿色集团（股份编号：01397） 成立于1980年，是香港最大和最受敬重的综合环境服务集团之一，提供环卫星保洁、资源回收、循环再造、废物管理、绿色科技、有机肥料及动物饲料生产、园艺绿化工程及害虫防治等。集团为不同领域的客户提供服务，包括政府部门、各大机构和跨国企业。集团努力不懈地提升环境、社会和管治（ESG）的表现，以推进集团的可持续发展，以实现将香港推动成为更清洁、更绿色、更健康城市的愿景。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
MHI Group to Begin Demonstration Testing of Automated Valet Parking System Using AGV Robots at Outlet Mall in Chiba JCN Newswire

MHI Group to Begin Demonstration Testing of Automated Valet Parking System Using AGV Robots at Outlet Mall in Chiba

13 6 月, 2022
TOKYO, Jun 13, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) and Mitsubishi Heavy Industries Machinery Systems, Ltd. today launched demonstration testing of an automated valet parking system at a large-scale commercial facility near Tokyo. The system employs automated guided vehicle (AGV) robots, dubbed "Stan," manufactured by Stanley Robotics, a French venture-backed company. The event marks the first application of this type of autonomous vehicle handling system in a commercial complex in Japan.Automated valet parkingImage of demonstration testing areaStanley Robotics' AGV robot "Stan"The demonstration testing will be performed with cooperation from Mitsubishi Estate Group. It will take place in a designated parking zone at Shisui Premium Outlets', an outlet mall located in Chiba Prefecture which is operated by Mitsubishi Estate.Simon Co., Ltd. Vehicles will be transported autonomously by AGV robots in an environment close to actual application, to verify handling performance and evaluate user satisfaction.MHI Group is targeting nationwide deployment of automated valet parking systems as well as automated systems for transporting finished vehicles. Working in collaboration with Stanley Robotics, a world leader in the development and deployment of automated valet parking systems using AGV robots, MHI Group has been undertaking demonstration testing at MHI facility since October 2021. Now, with the data to be acquired through demonstration testing at a real commercial complex, MHI Group will further accelerate its initiatives toward achieving these services' commercial viability in Japan.MHI Group, as part of its growth strategy under its 2021 Medium-Term Business Plan, is currently taking steps to develop its solutions business through achievement of smart social infrastructures, in a quest to realize a carbon neutral society. This project is one of various initiatives MHI Group is working on to support "CASE"* era infrastructure. By taking the lead in providing AGV robot-based automated valet parking services at shopping malls, commercial complexes, amusement parks, airports, etc., MHI Group will contribute to the realization of a safe, comfortable and sustainable society.*"CASE" is an acronym derived from the words "connected," "autonomous," "shared" and "electric." It refers to the current technological trend in the automotive industry to create next-generation mobility services that offer outstanding safety and convenience.Concepts behind AGV robot-based automated valet parking1. Arrival: The customer parks in one of the "berths" installed next to the facility, and simply drop off the vehicle. There is no need to search for a parking space or to walk from a distant parking space even in inclement weather.2. Automated transportation: The AGV robot automatically transports the vehicle to a designated parking space. Robot-assisted parking enables more efficient use of limited space, to increase parking capacity. Storing the vehicle in the segregated parking area also prevents accidents or thefts.3. Reservation for departure: The customer can simply make a reservation for departure at any time by smartphone app. As the reservation time approaches, the vehicle is automatically transported to the berth. Since the customer can confirm the vehicle status by app, it is possible to continue shopping, dining, etc. thus making more effective use of time.4. Departure: The vehicle is available for pick-up at the berth at the reserved time, so there is no waiting. The berth is spacious, enabling easy loading of passengers and packages comfortably without stress.Automated valet parking demonstration test profile:Location: Shisui Premium Outlets' parking zone P9Schedule: June 13 (Mon) through July 1 (Fri), 2022 (subject to change)How Stanley Robotics' AGV robot "Stan" operatesThe AGV robot "Stan" equips with a platform that lifts the vehicle's 4 wheels, and automatically transports the vehicle indoors or outdoors. This robot has started commercial operation from 2018 in a parking garage at Lyon-Saint Exupery Airport in France, and has subsequently gone into service at Gatwick Airport in London.About Stanley RoboticsStanley Robotics is a deep tech company that combines hardware and software to provide solutions for outdoor logistics. The technology lies in a robot lifting and moving cars autonomously and in an intelligent storage management software. Robotics has transformed indoor logistics (e.g. in warehouses), resulting in a spectacular increase of productivity. Stanley Robotics' ambition is to bring this transformation to outdoor logistics with its proprietary technologies.Founded in 2015, the SME is headquartered in Paris, France, and is also behind the world's first outdoor robotic valet parking service. For more information, visit https://stanley-robotics.com/en/About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More